sulfasalazine has been researched along with Lung Neoplasms in 9 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 5.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| " Events included eight patients with malignancies, two with pancytopenia taking methotrexate, three with septic arthritis, and two with septicaemias." | 3.71 | Monitoring and assessing the safety of disease-modifying antirheumatic drugs: a West Midlands experience. ( Bevan, J; Homer, D; Jobanputra, P; Maggs, F, 2002) |
| " Chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer were enrolled in a dose-escalation study (standard 3 + 3 design) of SASP in combination with cisplatin and pemetrexed." | 2.84 | Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. ( Fujita, A; Harada, T; Hirai, F; Imamura, CK; Inada, M; Iwama, E; Kishimoto, J; Mushiroda, T; Nagano, O; Nakanishi, Y; Nosaki, K; Ogata, H; Okamoto, I; Otsubo, K; Ozeki, T; Sakata, S; Saya, H; Seto, T; Suina, K; Takenoyama, M; Toyokawa, G; Tsuchihashi, K, 2017) |
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 1.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| "Cachexia is a relevant comorbid condition of chronic diseases including cancer." | 1.40 | Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. ( Barreiro, E; Chacon-Cabrera, A; de Kier Joffé, ED; Diament, MJ; Fermoselle, C; Mateu-Jimenez, M; Sandri, M; Urtreger, AJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Bagherpoor, AJ | 1 |
| Shameem, M | 1 |
| Luo, X | 1 |
| Seelig, D | 1 |
| Kassie, F | 1 |
| Otsubo, K | 1 |
| Nosaki, K | 1 |
| Imamura, CK | 1 |
| Ogata, H | 1 |
| Fujita, A | 1 |
| Sakata, S | 1 |
| Hirai, F | 1 |
| Toyokawa, G | 1 |
| Iwama, E | 1 |
| Harada, T | 1 |
| Seto, T | 1 |
| Takenoyama, M | 1 |
| Ozeki, T | 1 |
| Mushiroda, T | 1 |
| Inada, M | 1 |
| Kishimoto, J | 1 |
| Tsuchihashi, K | 1 |
| Suina, K | 1 |
| Nagano, O | 1 |
| Saya, H | 1 |
| Nakanishi, Y | 1 |
| Okamoto, I | 1 |
| Chacon-Cabrera, A | 1 |
| Fermoselle, C | 1 |
| Urtreger, AJ | 1 |
| Mateu-Jimenez, M | 1 |
| Diament, MJ | 1 |
| de Kier Joffé, ED | 1 |
| Sandri, M | 1 |
| Barreiro, E | 1 |
| Oiwa, H | 1 |
| Mihara, K | 1 |
| Kan, T | 1 |
| Tanaka, M | 1 |
| Shindo, H | 1 |
| Kumagai, K | 1 |
| Sugiyama, E | 1 |
| Guan, J | 1 |
| Lo, M | 1 |
| Dockery, P | 1 |
| Mahon, S | 1 |
| Karp, CM | 1 |
| Buckley, AR | 1 |
| Lam, S | 1 |
| Gout, PW | 1 |
| Wang, YZ | 1 |
| Ohara, G | 1 |
| Satoh, H | 1 |
| Kohno, M | 1 |
| Goto, D | 1 |
| Sumida, T | 1 |
| Hizawa, N | 1 |
| Jobanputra, P | 1 |
| Maggs, F | 1 |
| Homer, D | 1 |
| Bevan, J | 1 |
| Lay, JD | 1 |
| Hong, CC | 1 |
| Huang, JS | 1 |
| Yang, YY | 1 |
| Pao, CY | 1 |
| Liu, CH | 1 |
| Lai, YP | 1 |
| Lai, GM | 1 |
| Cheng, AL | 1 |
| Su, IJ | 1 |
| Chuang, SE | 1 |
| Awasthi, S | 1 |
| Sharma, R | 1 |
| Singhal, SS | 1 |
| Herzog, NK | 1 |
| Chaubey, M | 1 |
| Awasthi, YC | 1 |
1 trial available for sulfasalazine and Lung Neoplasms
| Article | Year |
|---|---|
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small | 2017 |
8 other studies available for sulfasalazine and Lung Neoplasms
| Article | Year |
|---|---|
Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung | 2023 |
Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Butadienes; Cachexia; Cell Line, Tumor; Inflammation; | 2014 |
Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Female; Glucocorticoids; Humans; Lung Neoplasms; Lymphomatoid Granulomat | 2014 |
The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
Topics: Amino Acid Transport System y+; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transpo | 2009 |
Development of rheumatoid arthritis during the course of gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interaction | 2009 |
Monitoring and assessing the safety of disease-modifying antirheumatic drugs: a West Midlands experience.
Topics: Antirheumatic Agents; Arthritis, Infectious; Azathioprine; Drug Monitoring; Humans; Hypokalemia; Lun | 2002 |
Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Cell L | 2007 |
Modulation of cisplatin cytotoxicity by sulphasalazine.
Topics: Carcinoma, Small Cell; Cisplatin; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; | 1994 |